SCHEMBL21725564

SCHEMBL21725564

CCOc1nccnc1SC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
HPGD P15428 1/20 0.41
GRM5 P41594 1/20 0.39
LRRK2 Q5S007 1/20 0.36
RAB9A P51151 3/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
NQO1 P15559 1/20 0.32
CHRM1 P11229 1/20 0.32
L3MBTL1 Q9Y468 3/20 0.32
NPC1 O15118 1/20 0.32
MITF O75030 1/20 0.32
PKM P14618 1/20 0.32
LMNA P02545 2/20 0.32
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.31
CASP3 P42574 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7598688 0.78 HPGD (0.52) SMN1; SMN2HPGDGRM5LRRK2RAB9A
SCHEMBL29728888 0.76 TSHR (0.31) RAB9AL3MBTL1LMNATSHRCASP3
Ammonia Solution, Strong SCHEMBL28789679 0.76 HPGD (0.50) SMN1; SMN2HPGDGRM5LRRK2RAB9A
SCHEMBL2585538 0.73 SMN1; SMN2 (0.44) SMN1; SMN2HPGDGRM5LRRK2RAB9A
SCHEMBL22661734 0.72 TP53 (0.34) HPGDRAB9AKMT2AMEN1L3MBTL1
SCHEMBL2490706 0.70 HPGD (0.45) SMN1; SMN2HPGDGRM5LRRK2KMT2A
SCHEMBL301725 0.70 PDE3B (0.32) RAB9AL3MBTL1TSHRCASP3SENP8
SCHEMBL16579445 0.70 HPGD (0.45) SMN1; SMN2HPGDGRM5LRRK2KMT2A
SCHEMBL21725435 0.69 L3MBTL1 (0.45) SMN1; SMN2HPGDGRM5RAB9AL3MBTL1
SCHEMBL21725476 0.69 GRM5 (0.46) SMN1; SMN2HPGDGRM5RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-01-07 US disclosed
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R SMN1; SMN2 2938/4885HPGD 1592/4885GRM5 300/4885
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R SMN1; SMN2 2938/4885HPGD 1592/4885GRM5 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.